R-Biopharm AG

R-Biopharm AG is a specialized company focused on developing innovative diagnostic solutions for clinical diagnostics and food analysis, enhancing health and safety standards across multiple sectors. Founded in 1988 and headquartered in Darmstadt, Germany, R-Biopharm AG develops diagnostic solutions addressing various health concerns. The company has undergone two notable deals, with the most recent being a Buyout in August 2009, where BWK acquired a minority stake for EUR 1. 3 million.

The company has not pivoted significantly in its strategy or operations since its inception. CEO Roberto Comitti leads the company, which has not been reported as part of a parent firm or having subsidiaries. R-Biopharm AG specializes in the development and provision of a diverse range of innovative diagnostic solutions aimed at the clinical diagnostics and food analysis sectors. The company’s diagnostic offerings address various health concerns and promote wellbeing, prevention, and therapeutic monitoring.

R-Biopharm's products facilitate reliable food and feed analysis, ensuring safety and compliance with industry standards. Their client base includes healthcare providers, laboratories, and food manufacturers, primarily serving markets in Europe, Asia, and North America. R-Biopharm is committed to enhancing health outcomes through personalized and sophisticated diagnostics tailored to meet customer needs. R-Biopharm AG generates revenue through a business-to-business (B2B) model, supplying its diagnostic products to laboratories, healthcare institutions, and food safety companies.

The company reported a revenue of EUR 265,433,307. 30 and an EBITDA of EUR 80,488,667. 40 for the year 2020. Transactions typically involve bulk orders of diagnostic kits and reagents, essential for various applications in clinical and food safety testing, with flagship products contributing significantly to revenue due to their regulatory compliance and market demand.

R-Biopharm AG aims to expand its portfolio by launching several new diagnostic products in the upcoming years, although specific release dates have yet to be announced. The company is also focused on penetrating new markets, particularly in Asia and North America, by 2025. The funding acquired from BWK in August 2009 will support these initiatives, enabling R-Biopharm to enhance its product development and market expansion strategies.